
Opinion|Videos|June 5, 2024
Evolving Commercialization and Distribution Models for PDTs
The panel discusses the challenges of delivering prescription digital therapeutics (PDTs) to patients, challenges caused by PDTs being considered behavioral health benefits, pharmacy benefits, medical benefits, and durable medical equipment benefits.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Diagnosing Alzheimer's Disease Agitation: Triggers, Care Specialties, and the Role of Primary Care
2
FDA Approves First Autoinjector for At-Home IV-Equivalent Diuresis
3
Defining Alzheimer's Disease Agitation: Diagnostic Criteria, Symptoms, and Disease Course
4
Small Workflow Changes Close Big Gaps in CKM Screening
5




